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that these fragments, which would normally be small enough
to be cleared by glomerular filtration, accumulate in the
circulation of patients with end-stage renal disease and
crossreact in immunoassays for cTnT.
Recent evidence, unavailable to Kanderian and Francis
when their paper was accepted, argues against this. Firstly,
cTnT concentrations are significantly increased among
patients with CKD long before end stage is reached
(i.e. when significant glomerular filtration remains).3
Secondly, using a direct gel-filtration chromatography
approach, we have shown that the form of cTnT circulating
in dialysis patients and reacting in the commercial cTnT
immunoassay is an intact, free form, identical in size to that
observed among non-CKD patients following an acute
coronary syndrome, with no evidence of smaller molecular
weight fragments.4 Diris et al.2 used a complex analytical
approach including the use of Western blotting, which is
known to be susceptible to artifact.
Much work is needed before the pathophysiology under-
lying cardiac troponin increases in CKD is fully understood.
However, it is important that this presentation is not
dismissed as an artifact due to fragment accumulation:
increases in CKD are real and predict death.
1. Kanderian AS, Francis GS. Cardiac troponins and chronic kidney disease.
Kidney Int 2006; 69: 1112–1114.
2. Diris JH, Hackeng CM, Kooman JP et al. Impaired renal clearance explains
elevated troponin T fragments in hemodialysis patients. Circulation 2004;
109: 23–25.
3. Abbas NA, John RI, Webb MC et al. Cardiac troponins and renal function
in non-dialysis patients with chronic kidney disease. Clin Chem 2005; 51:
2059–2066.
4. Fahie-Wilson MN, Carmichael DJ, Delaney MP et al. Fragments of cardiac
troponin T are not responsible for the elevated serum concentrations
observed in patients with kidney failure. Clin Chem 2006; 52: 414–420.
EJ Lamb1, EM Hall1 and M Fahie-Wilson2
1Department of Clinical Biochemistry, East Kent Hospitals NHS Trust, Kent
and Canterbury Hospital, Canterbury, Kent, UK and 2Department of
Biochemistry, Southend Hospital, Prittlewell Chase, Westcliff-on-Sea,
Essex, UK
Correspondence: Dr EJ Lamb, Department of Clinical Biochemistry, East
Kent Hospitals NHS Trust, Kent and Canterbury Hospital, Canterbury, Kent
CT1 3NG, UK. E-mail: edmund.lamb@ekht.nhs.uk
Response to ‘Cardiac troponins
and chronic kidney disease’
Kidney International (2006) 70, 1526. doi:10.1038/sj.ki.5001807
We thank Lamb et al.1 for bringing to our attention new
data regarding the mechanism of elevated circulating
troponin levels (cTnT) in patients with renal dysfunction.
We were unaware of their recently published results. Their
work indicates that it is the free-form cTnT that is being
measured in patients with chronic kidney disease (CKD),
identical in size to that of cTnT observed in non-renal
disease patients, and not a smaller fragment of cTnT as
suggested earlier by Diris et al.2 We agree that although the
mechanism of altered cTnT levels in CKD is not fully
understood, increased cTnT levels are consistently asso-
ciated with an incremental change in morbidity and
mortality, and cannot be dismissed as laboratory artifact.
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To the Editor: Little et al.1 recently analyzed post-
transplantation recurrence risk in patients with membrano-
proliferative glomerulonephritis (MPGN). They found that
age and crescents on initial biopsy determined this risk rather
than the type of MPGN. The authors suggest that type II
MPGN may not be very different from type I MPGN.
However, it is evident that type I and II MPGN are
pathologically and pathogenetically different entities. Like-
wise, membranous nephropathy and focal segmental glomer-
ulosclerosis are totally different diseases, although the
nephrotic syndrome rather than the diagnosis determines
outcome. Crescents may be a common risk factor for
recurrent disease, as has been suggested for immunoglobulin
A-nephropathy.2 From the data we cannot retrieve if clinically
silent recurrences of type II MPGN have been missed.
Furthermore, the multivariate analysis did not include
potential risk factors as repeated transplantation and living-
related donor transplantation.3 In our single-center studies,
we noted significant differences between type I and II MPGN
with regard to post-transplant recurrence. A recurrence of
type I MPGN occurred in almost 50% of recipients and was
invariably accompanied by clinically significant proteinuria.
Increased risk of recurrence was observed with human
lymphocyte antigen-identical living-related donor kidneys,
the human lymphocyte antigen-B8DR3 haplotype, and
repeated transplants.3 In contrast, all patients with type II
MPGN who had been biopsied (11 of 13) showed a
recurrence. Most recurrences were, however, clinically silent
and required immunofluorescence or electron microscopy for
diagnosis. Still, patients with type II MPGN had poor graft
survival. Crescents in the original biopsy were not specific
predictors.4
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We thank Dr Andresdottir1 for their comments. We fully
accept that membranoproliferative glomerulonephritis
(MPGN) types I and II are different in many ways,
although the comparison with focal segmental glomerulo-
sclerosis and membranous nephropathy is not accurate.
Both type I and II MPGNs are characterized by immune
complex deposition with a membranoproliferative pattern
of injury by light microscopy, associated clinically with
slowly progressive nephritis, proteinuria, and hypocom-
plementemia. It is thus reasonable, until a definitive
etiology is identified, to consider them together.
We also accept that clinically silent recurrence may
occur, although this was not evident on those recipients
who underwent biopsy for other indications such as
rejection. We felt, however, that clinical recurrence was a
more clinically relevant outcome to include in the multi-
variate analysis. Seven allografts were donated by a family
member, of which four (57%) developed recurrence (two
each in the MPGN types I and II groups). This value was
not significantly different from that seen in the group as a
whole (49%), although the numbers here are too small to
exclude a subtle effect.
With respect to repeated transplantation, identified as a
risk factor for recurrence in MPGN type I in Dr
Andresdottir and colleagues’ series of five patients, we
have re-analyzed our data. In our series, of the seven cases
re-transplanted, two were in the MPGN type I group and
neither of these developed recurrence, indicating that (in
our series) this is not predictive in re-transplantation. They
also state that crescents on the original biopsy were not
predictive of recurrence of type II MPGN. Unfortunately,
these data were not present in their published paper, so we
are unable to comment on this.
We certainly do not dispute the large body of evidence
indicating that patients with type II MPGN are more likely
to develop recurrent disease than other forms of MPGN.
Rather, we maintain that it is the presence of severe
histological features of crescentic glomerulonephritis
(which are over-represented in MPGN type II patients)
that have the most potent impact on recurrence.
1. Andresdottir MB, Assmann KJ, Hoitsma AJ, Koene RA, Wetzels JF.
Recurrence of type I membranoproliferative glomerulonephritis after
renal transplantation: analysis of the incidence, risk factors, and impact
on graft survival. Transplantation 1997; 63: 1628–1633.
MA Little1, P Dupont2, E Campbell2, A Dorman and JJ Walshe2
1Renal Section, Imperial College, Hammersmith Hospital, London, UK and
2Department of Nephrology and Transplantation, Beaumont Hospital,
Dublin
Correspondence: M Little, Renal Section, Imperial College, Hammersmith
Hospital, London W12ONN, UK. E-mail: m.little@imperial.ac.uk
Kidney International (2006) 70, 1523–1527 1527
l e t t e r t o t h e e d i t o r
